Trial: 202112042

EPIK-B4: A phase II, multi center, randomized, open-label, active controlled study to assess the safety and efficacy of dapagliflozin + metfromin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy

Phase

II (Cancer Control)

Principal Investigator

Peterson, Lindsay

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov